Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers

Gautham Ravipati, Wilbert S. Aronow, Chul Ahn, Rose M. Alappat, John A. McClung, Melvin B. Weiss

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We investigated in 306 patients, mean age 57 ± 10 years, with diabetes mellitus (202 patients) or hypertension (179 patients), whether treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) reduced the incidence of new stroke or new myocardial infarction (MI) or death. At 39-month follow up, new stroke or new MI or death developed in 49 of 228 patients (21%) treated with ACE inhibitors or ARBs and in 33 of 78 patients (42%) treated without angiotensin-converting enzyme inhibitors or ARBs (P = 0.0001). Stepwise Cox regression analysis showed that significant independent predictors of the time to development of new stroke or new MI or death were 1) use of angiotensin-converting enzyme inhibitors or ARBs (risk ratio, 0.21), 2) diabetes (risk ratio, 4.01), 3) left ventricular hypertrophy (risk ratio, 6.71), 4) prior stroke (risk ratio,4.00), and 5) prior MI (risk ratio, 3.69).

Original languageEnglish (US)
Pages (from-to)2-4
Number of pages3
JournalAmerican Journal of Therapeutics
Volume16
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Diabetes Mellitus
Stroke
Odds Ratio
Myocardial Infarction
Hypertension
Incidence
Left Ventricular Hypertrophy
Regression Analysis

Keywords

  • Angiotensin receptor blocker
  • Angiotensin-converting enzyme inhibitor
  • Diabetes mellitus
  • Hypertension
  • Left ventricular hypertrophy
  • Myocardial infarction
  • Stroke

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{0db957c8742f4f1383e8249063bf3dff,
title = "Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers",
abstract = "We investigated in 306 patients, mean age 57 ± 10 years, with diabetes mellitus (202 patients) or hypertension (179 patients), whether treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) reduced the incidence of new stroke or new myocardial infarction (MI) or death. At 39-month follow up, new stroke or new MI or death developed in 49 of 228 patients (21{\%}) treated with ACE inhibitors or ARBs and in 33 of 78 patients (42{\%}) treated without angiotensin-converting enzyme inhibitors or ARBs (P = 0.0001). Stepwise Cox regression analysis showed that significant independent predictors of the time to development of new stroke or new MI or death were 1) use of angiotensin-converting enzyme inhibitors or ARBs (risk ratio, 0.21), 2) diabetes (risk ratio, 4.01), 3) left ventricular hypertrophy (risk ratio, 6.71), 4) prior stroke (risk ratio,4.00), and 5) prior MI (risk ratio, 3.69).",
keywords = "Angiotensin receptor blocker, Angiotensin-converting enzyme inhibitor, Diabetes mellitus, Hypertension, Left ventricular hypertrophy, Myocardial infarction, Stroke",
author = "Gautham Ravipati and Aronow, {Wilbert S.} and Chul Ahn and Alappat, {Rose M.} and McClung, {John A.} and Weiss, {Melvin B.}",
year = "2009",
month = "1",
doi = "10.1097/MJT.0b013e31804d1b53",
language = "English (US)",
volume = "16",
pages = "2--4",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers

AU - Ravipati, Gautham

AU - Aronow, Wilbert S.

AU - Ahn, Chul

AU - Alappat, Rose M.

AU - McClung, John A.

AU - Weiss, Melvin B.

PY - 2009/1

Y1 - 2009/1

N2 - We investigated in 306 patients, mean age 57 ± 10 years, with diabetes mellitus (202 patients) or hypertension (179 patients), whether treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) reduced the incidence of new stroke or new myocardial infarction (MI) or death. At 39-month follow up, new stroke or new MI or death developed in 49 of 228 patients (21%) treated with ACE inhibitors or ARBs and in 33 of 78 patients (42%) treated without angiotensin-converting enzyme inhibitors or ARBs (P = 0.0001). Stepwise Cox regression analysis showed that significant independent predictors of the time to development of new stroke or new MI or death were 1) use of angiotensin-converting enzyme inhibitors or ARBs (risk ratio, 0.21), 2) diabetes (risk ratio, 4.01), 3) left ventricular hypertrophy (risk ratio, 6.71), 4) prior stroke (risk ratio,4.00), and 5) prior MI (risk ratio, 3.69).

AB - We investigated in 306 patients, mean age 57 ± 10 years, with diabetes mellitus (202 patients) or hypertension (179 patients), whether treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) reduced the incidence of new stroke or new myocardial infarction (MI) or death. At 39-month follow up, new stroke or new MI or death developed in 49 of 228 patients (21%) treated with ACE inhibitors or ARBs and in 33 of 78 patients (42%) treated without angiotensin-converting enzyme inhibitors or ARBs (P = 0.0001). Stepwise Cox regression analysis showed that significant independent predictors of the time to development of new stroke or new MI or death were 1) use of angiotensin-converting enzyme inhibitors or ARBs (risk ratio, 0.21), 2) diabetes (risk ratio, 4.01), 3) left ventricular hypertrophy (risk ratio, 6.71), 4) prior stroke (risk ratio,4.00), and 5) prior MI (risk ratio, 3.69).

KW - Angiotensin receptor blocker

KW - Angiotensin-converting enzyme inhibitor

KW - Diabetes mellitus

KW - Hypertension

KW - Left ventricular hypertrophy

KW - Myocardial infarction

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=60249097777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249097777&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e31804d1b53

DO - 10.1097/MJT.0b013e31804d1b53

M3 - Article

C2 - 19114876

AN - SCOPUS:60249097777

VL - 16

SP - 2

EP - 4

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 1

ER -